Recent advances of antibody drug conjugates for clinical applications
Data
2020Autor
Zhao, Pengxuan
Zhang, Yuebao
Li, Wenqing
Jeanty, Christopher
Xiang, Guangya
Metadata
Mostrar registro completo
Documentos PDF
Resumo
Antibody drug conjugates (ADCs) normally compose of a humanized
antibody and small molecular drug via a chemical linker. After decades of preclinical
and clinical studies, a series of ADCs have been widely used for treating specific
tumor types in the clinic such as brentuximab vedotin (Adcetris®
) for relapsed
Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab
ozogamicin (Mylotarg®
) for acute myeloid leukemia, ado-trastuzumab emtansine
(Kadcyla®
) for HER2-positive metastatic breast cancer, inotuzumab ozogamicin (Besponsa®
) and most recently polatuzumab vedotin-piiq (Polivy
®
) for B cell
malignancies. More than eighty ADCs have been investigated in different clinical
stages from approximately six hundred clinical trials to date. This review summarizes
the key elements of ADCs and highlights recent advances of ADCs, as well as
important lessons learned from clinical data, and future directions.
Palabras clave
Antibody drug conjugates; Antibody; Cytotoxic agents; Linker; Clinical applicationLink para o recurso
https://doi.org/10.1016/j.apsb.2020.04.012Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.